文献速递消化道肿瘤与早癌消化内镜

筛查年龄降至45岁背景下患者对结直肠癌筛查试验的偏好

Patient Preferences for Colorectal Cancer Screening Tests in Light of Lowering the Screening Age to 45 Years.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-07-20

该研究采用联合分析调查≥40岁平均风险未筛查人群对结直肠癌筛查试验属性的偏好,并模拟美国多学会工作组推荐试验的偏好比例。1000名参与者中,40-49岁456人、≥50岁544人;最偏好每3年一次粪便免疫化学试验-粪便DNA检测,40-49岁为34.6%、≥50岁为37.3%;仅考虑一级推荐试验时,40-49岁68.9%、≥50岁77.4%偏好每年粪便免疫化学试验而非每10年结肠镜(P=.004)。结论提示超过三分之一的人可能选择每3年一次粪便免疫化学试验-粪便DNA检测。

要点

  • 最偏好每3年一次粪便免疫化学试验-粪便DNA检测:40-49岁34.6%、≥50岁37.3%。
  • 仅考虑一级推荐试验时,偏好每年粪便免疫化学试验者40-49岁68.9%、≥50岁77.4%(P=.004)。
  • 不同年龄组对5种推荐试验的偏好存在差异(P=.019)。

核心结论

  • 研究提示超过三分之一的人可能希望每3年进行一次粪便免疫化学试验-粪便DNA检测用于结直肠癌筛查。
  • 仅考虑美国多学会工作组一级推荐试验时,四分之三的人可能偏好每年粪便免疫化学试验而非结肠镜。
  • 作者认为需要进一步研究更广泛人群的结直肠癌筛查试验偏好,以指导和改进筛查项目。

研究设计与样本

  • 采用联合分析调查≥40岁平均风险未筛查个体,评估筛查试验属性在决策中的相对重要性。
  • 共1000名参与者完成联合分析,其中40-49岁456人、≥50岁544人。
  • 通过模拟估计偏好每种美国多学会工作组推荐试验的人群比例,并按年龄分层分析。

主要发现

  • 考虑全部5种美国多学会工作组推荐试验时,年龄组间试验偏好存在差异(P=.019)。
  • 最偏好每3年一次粪便免疫化学试验-粪便DNA检测:40-49岁34.6%、≥50岁37.3%。
  • 仅考虑美国多学会工作组一级推荐试验时,偏好每年粪便免疫化学试验而非每10年结肠镜者40-49岁68.9%、≥50岁77.4%(P=.004)。

关键数值与推荐

  • 最偏好试验为每3年一次粪便免疫化学试验-粪便DNA检测,40-49岁34.6%、≥50岁37.3%。
  • 仅考虑一级推荐试验时,偏好每年粪便免疫化学试验者40-49岁68.9%、≥50岁77.4%(P=.004)。
  • 全部5种推荐试验的偏好年龄组间差异P=.019。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需要进一步研究更广泛人群的结直肠癌筛查试验偏好,以指导和改进筛查项目。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In 2021, the US Preventive Services Task Force lowered the colorectal cancer (CRC) screening age to 45 years. We used conjoint analysis, a method that assesses complex decision making, to update our understanding on people's CRC screening test preferences in the context of new guidelines. METHODS: We conducted a conjoint analysis survey among unscreened individuals ≥40 years at average risk for CRC to determine the relative importance of screening test attributes in their decision making (eg, modality, effectiveness at reducing CRC risk, bowel prep). We also performed simulations to estimate the proportion of people who would prefer each US Multi-Society Task Force (MSTF) on CRC-recommended test. The analyses were stratified among those aged 40-49 years (newly or soon-to-be eligible for screening) and ≥50 years (have been eligible). RESULTS: Overall, 1000 participants completed the conjoint analysis (40-49 years, n = 456; ≥50 years, n = 544). When considering all 5 US MSTF-recommended tests, there were differences in test preferences between age groups (P = .019), and the most preferred test was a fecal immunochemical test (FIT)-fecal DNA every 3 years: 40-49 years, 34.6%; ≥50 years, 37.3%. When considering only the US MSTF tier 1 tests, most 40- to 49- (68.9%) and ≥50-year-olds (77.4%; P = .004) preferred an annual FIT over a colonoscopy every 10 years. CONCLUSIONS: Our findings suggest that more than one-third of people may want to do a FIT-fecal DNA every 3 years for their CRC screening. When only considering US MSTF tier 1 tests, three-fourths of people may prefer an annual FIT over colonoscopy. Further research examining CRC screening test preferences among broader populations is warranted to inform and enhance screening programs.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Makaroff KE, Shergill J, Lauzon M, et al. Patient Preferences for Colorectal Cancer Screening Tests in Light of Lowering the Screening Age to 45 Years. Clin Gastroenterol Hepatol. 2022. PMID: 35870766. doi:10.1016/j.cgh.2022.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。